Exploratory clinical study to evaluate the potential bioactivity of CLBS14 in patients with coronary microvascular dysfunction
Ended Project Grant Awarded Last action
- Award ID
- R44HL135889
- Recipient
-
Lisata Therapeutics Inc. UEI USWTE8MPR7H1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,723,324
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Funding
-
- $1,795,982.38 Federal
- -$72,658.81 Non-federal
- Place of performance
- Basking Ridge, Bernards, NJ, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$72,659 | $0 | |
| Amendment | -$72,659 | -$72,659 | |
| Amendment | $0 | $0 | |
| Amendment | $214,260 | $0 | |
| Amendment | $973,475 | $0 | |
| Original award | $753,565 | $0 |
Quick answers
Who received award R44HL135889?
R44HL135889 was awarded to Lisata Therapeutics Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 20, 2017.
How much is award R44HL135889 worth?
$1,723,324 has been obligated on R44HL135889: $1,795,982 in federal funding and -$72,659 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award